Navigation Links
Taligen Therapeutics Secures Series B Financing
Date:2/1/2008

AURORA, Colo., Feb. 1 /PRNewswire/ -- Taligen Therapeutics, Inc. today announced it anticipates receiving up to $65 million in a tranched Series B financing. The financing was led by Alta Partners and Clarus Ventures with participation from existing investors, including Sanderling Ventures, Tango and High Country Venture.

"This Series B round represents not only an infusion of capital but the addition of two world class investor groups, Alta Partners and Clarus Ventures, represented on our Board respectively by Edward Hurwitz and Nicholas Galakatos, PhD," said Timothy Mills, PhD, Chairman of the Board of Taligen. "The progress made since our original investment in 2005 now allows us to develop multiple products to control the alternative pathway of complement activation. With this additional funding, we expect to move into clinical development with all of our lead candidates."

About Taligen: Founded in 2004, Taligen Therapeutics, Inc. is a development-stage biotechnology company with novel technology and expertise focused on modulation and control of the complement system. The complement system is believed to be a critical component in the initiation of inflammation. Complement system activation is characteristic of many human diseases, including asthma, macular degeneration, rheumatoid arthritis and immune renal disease.

Taligen's lead products are monoclonal antibodies and recombinant fusion proteins which target key factors in the alternative complement pathway. These products are in preclinical stages of development to treat systemic as well as local inflammatory conditions.

The Company was founded by Drs. Woodruff Emlen and V. Michael Holers based on technology and intellectual property predominantly from the University of Colorado at Denver and Health Sciences Center (UCDHSC) and partnering institutions. Dr. Holers is currently Professor of Medicine at UCDHSC and Dr. Emlen is a former Professor of Medicine and Immunology at U
'/>"/>

SOURCE Taligen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
3. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
4. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
5. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
6. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
10. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
11. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Green & Grow Inc. ... B funding and secured Otter Capital as a significant ... accelerate commercialization of GGI’s Agriplier™ technology, building on recent ... , “Since our first meeting, we have been impressed ... product space,” said Alan Sobba, President and CEO of ...
(Date:8/27/2014)... Rhythm, a biopharmaceutical company developing peptide therapeutics that address ... disorders, announced today that it has filed a registration ... Exchange Commission (SEC) relating to the proposed initial public ... of shares to be offered and the price range ... Citigroup and Cowen and Company will act as ...
(Date:8/27/2014)... California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security LLC ... to develop and deliver a state-of-the-art laser system ... facility (ELI Beamlines), under construction in the Czech ... performance, the laser system, called the " High ...
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that ... in its catalogue: Global Biodegradable ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable ... are readily decomposed by the action of ... packaging in terms of raw materials, production ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7
... Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that ... on Wednesday, November 17, 2010 at 11:30 a.m. EST (8:30 ... Regis New York.  Steve Worland, Ph.D., President and Chief Executive ... its clinical development programs. The presentation will be ...
... Inc. announced today that the company has raised $7.1 ... The Series C round, which included 5 new investors, ... product VeriStrat®, a serum proteomic test that helps physicians ... (NSCLC). Existing shareholders of the company provided $5.1 million ...
... Business Unit Again Receives ,Best Places to Work in... -- SOUDERTON, Pennsylvania, November 10, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference 2Biodesix Completes Series C Financing and Receives Grant 2Biodesix Completes Series C Financing and Receives Grant 3Almac's Clinical Technologies Business Unit Again Receives 'Best Places to Work in PA 2010' Award 2Almac's Clinical Technologies Business Unit Again Receives 'Best Places to Work in PA 2010' Award 3Almac's Clinical Technologies Business Unit Again Receives 'Best Places to Work in PA 2010' Award 4Almac's Clinical Technologies Business Unit Again Receives 'Best Places to Work in PA 2010' Award 5Almac's Clinical Technologies Business Unit Again Receives 'Best Places to Work in PA 2010' Award 6Almac's Clinical Technologies Business Unit Again Receives 'Best Places to Work in PA 2010' Award 7
(Date:8/27/2014)... mechanical force that a single fungal cell or bacterial colony ... it plays a heavy role in setting up some of ... may not be too much of a stretch to say ... ability to respond to the touch of beneficial fungi, according ... of agronomy at the University of Wisconsin-Madison. , "Many ...
(Date:8/27/2014)... Calif. , Aug. 27, 2014  WaferGen Bio-systems, ... its previously announced underwritten public offering of units of ... per unit for gross proceeds of $20 million, prior ... payable by the Company.  The shares and warrants are ... Each unit sold in the offering consists of ...
(Date:8/27/2014)... mastodons, short-faced bears, giant ground sloths, saber-toothed cats and ... years ago at the end of the Pleistocene period. ... debated by scientists who, until recently, could only speculate ... UC Santa Barbara,s James Kennett, professor emeritus in the ... with Earth played a major role in the extinction. ...
Breaking Biology News(10 mins):A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3
... 12th International Coral Reef Symosium will bring together ... their science and hear their latest advances from ... research and findings are fundamental in informing international ... and sustainable use of coral reefs. WHAT: 12th ...
... are buzzing once again, and with that comes the threat ... Li Ka Shing Institute of Virology in the Faculty of ... end to this potentially serious infection. , West Nile ... and some in cases, infected people show no symptoms at ...
... The most common ailment to affect a horse is ... a way to detect this problem using a motion detection ... professor of equine surgery in the College of Veterinary Medicine ... lameness earlier than veterinarians using the traditional method of a ...
Cached Biology News:12th International Coral Reef Symposium 2Researchers moving towards ending threat of West Nile virus 2Motion sensors detect horse lameness earlier than veterinarians, MU study finds 2
... serum is collected from fasted mixed breed, mixed ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
Whole blood is collected from canines (any breed, either sex), refrigerated within 6 hours, processed within 24 hours and frozen at -20C....
Designed for flow cytometric applications intended to identify...
Biology Products: